TWF2 (twinfilin actin binding protein 2) is an actin-binding protein that inhibits actin polymerization by sequestering G-actin monomers and capping barbed ends of filaments 1. This dual mechanism regulates cellular motility and cytoskeletal dynamics, with roles in clathrin-mediated endocytosis and dendritic spine morphology 2. In cancer biology, TWF2 has emerged as an important oncogenic driver. In renal cell carcinoma (RCC), TWF2 is markedly upregulated in sunitinib-resistant cells and promotes tumor progression, invasion, and metastasis by suppressing Hippo signaling 3. Mechanistically, TWF2 stabilizes Yes-associated protein (YAP) by preventing its ubiquitination and degradation, with critical binding occurring at M99 residue 3. TWF2 is part of a broader pan-cancer oncogenic program across multiple malignancies 4. In hepatocellular carcinoma, TWF2 expression is significantly downregulated following CHAF1B knockdown, correlating with reduced tumor growth 5. Clinically, TWF2 methylation status serves as a prognostic marker for clear cell RCC survival, independent of standard clinical factors 6. Additionally, TWF2 has been identified as a potential biomarker for cytokine release syndrome in CAR-T therapy 7. In platelet biology, TWF2-mediated actin dynamics regulate platelet reactivity and hemostasis through n-cofilin and profilin 1 pathways 1.